Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRT-YHD_001
- Development stage
- Preclinical
- Lead developer
- NEORNAT
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
NRT-YHD_001 is a GalNAc-conjugated modified antisense microRNA targeting let-7i-5p, developed by NEORNAT Inc. as a macrophage checkpoint inhibitor for the treatment of hepatocellular carcinoma (HCC). By selectively inhibiting let-7i-5p, the drug functions as a regulator of macrophage activation within the tumor microenvironment, promoting phagocytosis and demonstrating superior antitumor efficacy compared to sorafenib in preclinical models. The compound is designed for liver-specific delivery via GalNAc conjugation and is administered intravenously. NRT-YHD_001 has completed IND-enabling studies, with regulatory submissions to the MFDS (Korea) and FDA (U.S.) planned for 2026.
- Other names
- NRT-YHD_001
02
Targets
let-7i-5p (microRNA let-7i-5p)
Beyond the preview
Go deeper on NRT-YHD_001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRT-YHD_001.